Immunogenik is a clinical‑stage biotechnology company developing first‑in‑class immunotherapies that overcome the trafficking and resistance barriers of solid tumors. Our lead program, 8R‑70CAR, recently received FDA Orphan Drug Designation for pediatric high‑grade glioma and is advancing under an active IND with early human clinical experience. Supported by multiple NIH STTR awards and a growing IP portfolio spanning CAR T, antibody, and immune‑modulating platforms, Immunogenik is building the next generation of solid‑tumor immunotherapy.
Immunogenik holds exclusive option agreements to the underlying technologies, ensuring a strong intellectual property position as we advance toward clinical and commercial translation.
The video (https://doi.org/10.1016/j.actbio.2023. 09. 042) shows CD70 CAR T cells (green) attacking and killing glioblastoma tumor cells (red).
Lead Program: 8R-70CAR T-Cell Therapy
Overview
8R-70CAR combines CD70 targeting with an IL-8 receptor modification to overcome barriers of solid tumor entry and enhance therapeutic efficacy.
Scientific and Clinical Highlights
Technology Origin
The platform originated from research conducted at the University of Florida and is currently under an exclusive licensing option with Immunogenik. Supporting scientific findings have been published in peer-reviewed journals (PMC6728370).
Platform 2: LAIR1 Antibody Blockade Therapy
Overview
aLAIR1 is a humanized monoclonal antibody that blocks LAIR1, a key immune-inhibitory receptor on tumor-associated myeloid cells. LAIR1 blockade reshapes the tumor microenvironment, reduces immune suppression, and enhances antitumor response.
Scientific and Clinical Highlights
Technology Origin
The LAIR1 blockade platform was developed through academic research (PMC12352909) at the University of Florida and is supported by NIH STTR funding. Immunogenik holds an exclusive option agreement for commercialization and licensing rights related to this technology platform.
Platform 3: 3-in-1 CAR T-Cell Therapy
A multifunctional CAR T-cell platform engineered to overcome tumor immune resistance (solid tumor ecosystem therapy) by integrating antigen recognition, enhanced T-cell trafficking, and intrinsic immune checkpoint blockade (PMC12352909). This next‑generation technology is currently in IND‑enabling development and is supported by an NIH STTR award, including Technical and Business Assistance (TABA) resources to accelerate commercialization planning and regulatory strategy.
Immunogenik is also exploring T-cell receptor (TCR)-based therapies for intracellular tumor antigens in solid and hematologic cancers. This work is in the early discovery phase and is being developed in collaboration with academic research at the University of Florida. Future licensing opportunities will be evaluated as the platform matures.
Haipeng Tao, et al
Linchun Jin, et al.
Ezri P. Perrin, et al
Linchun Jin, et al.
Duy T. Nguyen, et al
